Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 8/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182893 | 0.99 | FABP4 (0.49) | FABP4FABP3MEN1KMT2ASIGMAR1 | |
| SCHEMBL4218086 | 0.89 | FABP4 (0.50) | FABP4SIGMAR1TSHRPTGER4KCNK3 | |
| SCHEMBL2870198 | 0.89 | PTGER4 (0.48) | FABP4FABP3MEN1KMT2ASIGMAR1 | |
| SCHEMBL2843685 | 0.89 | PTGER4 (0.48) | FABP4FABP3MEN1KMT2ASIGMAR1 | |
| SCHEMBL10216949 | 0.89 | MEN1 (0.48) | FABP4FABP3MEN1KMT2ASIGMAR1 | |
| SCHEMBL5807508 | 0.89 | MAPT (0.46) | FABP4FABP3MEN1KMT2ATSHR | |
| SCHEMBL5806383 | 0.88 | FABP4 (0.49) | FABP4FABP3KMT2AGAATSHR | |
| SCHEMBL5079503 | 0.85 | CCNA2 (0.47) | FABP4FABP3MEN1KMT2ASIGMAR1 | |
| SCHEMBL5811567 | 0.84 | CYP2C9 (0.48) | SIGMAR1GAAPOLBKCNK3 | |
| SCHEMBL2715130 | 0.83 | MEN1 (0.45) | FABP4FABP3MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | claimed |
| JP-2009508953-A | — | — | 2009-03-05 | — | — | JP | claimed |
| EP-1937259-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | claimed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | claimed |
| WO-2007038036-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | CNR2, CNR1, FAAH | FABP4 2279/4885FABP3 963/4885MEN1 4260/4885 |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | FABP4 2279/4885FABP3 963/4885MEN1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.